Otonomy Shares Drop 54% After Hearing-Loss-Therapy-Study Results

Dow Jones

Oct 14, 2022

By Kathryn Hardison

Shares of Otonomy Inc. plummeted 54%, to 12 cents, on Thursday after it said higher doses of its hearing-loss therapy didn't demonstrate meaningful improvement for patients across multiple speech-in-noise hearing tests.

The biopharmaceutical company said the clinical evaluation was of higher doses for OTO-413. The results compare with the positive clinical results observed with lower doses of the therapy versus a placebo in prior studies.

The company said the lack of activity may be due to a complex dose-response relationship that has been observed with neurotrophins.

Otonomy said it intends to explore strategic options to advance and realize value from its pipeline, including OTO-413 and OTO-825, its gene-therapy program for congenital hearing loss.

Shares were 94% lower for the year.

Write to Kathryn Hardison at kathryn.hardison@wsj.com

(END) Dow Jones Newswires

October 13, 2022 13:20 ET (17:20 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2275678253"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2275678253\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2275678253?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-10-14 01:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2275678253","market":"us","top_or_hot":-1,"title":"Otonomy Shares Drop 54% After Hearing-Loss-Therapy-Study Results","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Kathryn Hardison \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/OTIC\">Otonomy</a> Inc. plummeted 54%, to 12 cents, on Thursday after it said higher doses of its hearing-loss therapy didn't demonstrate meaningful improvement for patients across multiple speech-in-noise hearing tests. \n</p>\n<p>\n  The biopharmaceutical company said the clinical evaluation was of higher doses for OTO-413. The results compare with the positive clinical results observed with lower doses of the therapy versus a placebo in prior studies. \n</p>\n<p>\n  The company said the lack of activity may be due to a complex dose-response relationship that has been observed with neurotrophins. \n</p>\n<p>\n  Otonomy said it intends to explore strategic options to advance and realize value from its pipeline, including OTO-413 and OTO-825, its gene-therapy program for congenital hearing loss. \n</p>\n<p>\n  Shares were 94% lower for the year. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Kathryn Hardison at kathryn.hardison@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 13, 2022 13:20 ET (17:20 GMT)\n</p>\n<p>\n  Copyright (c) 2022 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Otonomy Shares Drop 54% After Hearing-Loss-Therapy-Study Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOtonomy Shares Drop 54% After Hearing-Loss-Therapy-Study Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2022-10-14 01:20</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Kathryn Hardison \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/OTIC\">Otonomy</a> Inc. plummeted 54%, to 12 cents, on Thursday after it said higher doses of its hearing-loss therapy didn't demonstrate meaningful improvement for patients across multiple speech-in-noise hearing tests. \n</p>\n<p>\n  The biopharmaceutical company said the clinical evaluation was of higher doses for OTO-413. The results compare with the positive clinical results observed with lower doses of the therapy versus a placebo in prior studies. \n</p>\n<p>\n  The company said the lack of activity may be due to a complex dose-response relationship that has been observed with neurotrophins. \n</p>\n<p>\n  Otonomy said it intends to explore strategic options to advance and realize value from its pipeline, including OTO-413 and OTO-825, its gene-therapy program for congenital hearing loss. \n</p>\n<p>\n  Shares were 94% lower for the year. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Kathryn Hardison at kathryn.hardison@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 13, 2022 13:20 ET (17:20 GMT)\n</p>\n<p>\n  Copyright (c) 2022 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"http://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2275678253","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2275678253","pubTimestamp":1665681600,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"By Kathryn Hardison \n\n\n \n\n\n  Shares of Otonomy Inc. plummeted 54%, to 12 cents, on Thursday after it","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药"},"translate_title":"耳聋治疗研究结果公布后，耳道股价下跌54%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OTIC":1},"content_text":"By Kathryn Hardison \n\n\n \n\n\n  Shares of Otonomy Inc. plummeted 54%, to 12 cents, on Thursday after it said higher doses of its hearing-loss therapy didn't demonstrate meaningful improvement for patients across multiple speech-in-noise hearing tests. \n\n\n  The biopharmaceutical company said the clinical evaluation was of higher doses for OTO-413. The results compare with the positive clinical results observed with lower doses of the therapy versus a placebo in prior studies. \n\n\n  The company said the lack of activity may be due to a complex dose-response relationship that has been observed with neurotrophins. \n\n\n  Otonomy said it intends to explore strategic options to advance and realize value from its pipeline, including OTO-413 and OTO-825, its gene-therapy program for congenital hearing loss. \n\n\n  Shares were 94% lower for the year. \n\n\n \n\n\n  Write to Kathryn Hardison at kathryn.hardison@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 13, 2022 13:20 ET (17:20 GMT)\n\n\n  Copyright (c) 2022 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}